Medtronic Moves to Spin Off Diabetes Unit Amid Potential $250M–$350M Tariff Impact

On the same day, Medtronic also announced,Its diabetes business will operate independently and is expected to be completed through an IPO.

Que Dallara, current Executive Vice President of Medtronic and President of its Diabetes Business, will serve as the CEO of this soon-to-be-renamed diabetes technology company.

Company executives expect that this move will increase profit margins and earnings per share, while tariff policies may have the opposite effect.

Medtronic CEO Geoff Martha said on the company's earnings call: "Given the uniqueness of Medtronic's diabetes business in terms of customer base, market positioning, and supply chain infrastructure, the synergies of its commercial manufacturing and technology platforms are less applicable to the diabetes business.……This business separation transforms and simplifies our product portfolio, enabling us to focus more on the highest margin growth drivers.These growth drivers have been gaining momentum, and this increased focus will ensure that they fully realize their revenue growth potential."

Medtronic's stock price rose more than 1% after the market opened, reaching $87.69 per share. The S&P 500 index slightly declined.

BTIG Analysts Maintain Neutral Rating on Medtronic StockCalling the diabetes business spin-off plan the right move, as it is "going from small to big."

It is worth mentioning that at the beginning of this month (May 6), Medtronic announced the latest personnel appointment, and Kate Cronin will serve as the Chief Marketing Officer of its diabetes business.

This is another key personnel arrangement by the department following the April appointment of Dexcom's former executive Laura Endres as the head of the diabetes business in the Americas.

Cronin has many years of marketing experience.Cronin has been working at Moderna since 2021, responsible for promoting its COVID-19 vaccine.Last month, Kate Cronin had just left Moderna.

During his four-year tenure at Moderna, Cronin was responsible for building the company's brand and transitioning through the pandemic to an endemic phase.Adjusting Corporate Image During an Epidemic.

Prior to this, she had also worked at Ogilvy Health for 17 years, leaving the company as its global CEO.

Source: LinkedIn

Following the Restructuring of the Executive Team, Medtronic's Diabetes Business Enters a Period of Explosive Product Innovation:

At the end of last month, this medical technology giant announced that it had received FDA approval to pair its Simplera Sync glucose sensor with the MiniMed 780G insulin pump.

At the end of last year, Medtronic received FDA approval to launch a companion app designed to work with the InPen digital insulin pen and Simplera sensor.

At the same time, Medtronic is also seeking approval for an integrated diabetes management system that combines Medtronic's insulin pump and dosing algorithm with Abbott's continuous glucose monitoring technology, and submitted an application to the FDA at the end of last month.